Clinical trial
Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer
NCT02987777 is registered in ClinicalTrials.gov with Institut de Cancérologie de Lorraine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer
- Lead sponsor
- Institut de Cancérologie de Lorraine
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- August 31, 2016
- Enrollment
- 80 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
endometrial cancer